Litifilimab

Litifilimab (BIIB059) is a humanized anti-BDCA2 IgG1 monoclonal antibody administered subcutaneously. Litifilimab can inhibit the production of type I interferons, cytokines and chemokines. Litifilimab can be used in the research of diseases such as systemic lupus erythematosus[1][2].

Product Specifications

CAS Number

[2407378-48-5]

Product Name Alternative

BIIB059

UNSPSC

12352203

Target

C-type Lectin-like Receptors (CTLRs) ; Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/litifilimab.html

Purity

99.51

Solubility

10 mM in DMSO|H2O

Smiles

[Litifilimab]

Molecular Weight

(146.6 kDa)

References & Citations

[1]Cho SK, et al. Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus. Expert Opin Investig Drugs. 2023 May;32 (5) :345-353.|[2]Furie RA, et al. Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus. N Engl J Med. 2022 Sep 8;387 (10) :894-904.